We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
Trial record 8 of 62 for:    "cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy" OR "Cerebral Arterial Diseases"

EEG Monitoring in Children With Moyamoya Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03173014
Recruitment Status : Recruiting
First Posted : June 1, 2017
Last Update Posted : July 21, 2017
Information provided by (Responsible Party):
Hee-Soo Kim, Seoul National University Hospital

Brief Summary:
EEG in moyamoya disease in children preoperatively

Condition or disease Intervention/treatment
EEG With Periodic Abnormalities Device: EEG

Detailed Description:
EEG monitoring in children with moyamoy disease preoperatively for 10 minutes

Study Type : Observational
Estimated Enrollment : 10 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: EEG Finding in Moyamoya Disease in Children
Actual Study Start Date : June 30, 2017
Estimated Primary Completion Date : May 30, 2018
Estimated Study Completion Date : June 5, 2018

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Intervention Details:
    Device: EEG
    EEG monitoring

Primary Outcome Measures :
  1. EEG [ Time Frame: preoperative ]
    EEG finding

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   5 Years to 10 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
children with moyamoya disease from 5-10 years old

Inclusion Criteria:

  • moyamoya disease

Exclusion Criteria:

  • refusal

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03173014

Contact: Hee-Soo Kim 1052878006 dami0605@snu.ac.kr

Korea, Republic of
Hee-Soo Kim Recruiting
Seoul, Soul-t'ukpyolsi, Korea, Republic of, 03080
Contact: Hee-Soo Kim    1052878006    dami0605@snu.ac.kr   
Seoul National University Hospital Recruiting
Seoul, Korea, Republic of
Sponsors and Collaborators
Seoul National University Hospital
Principal Investigator: Hee-Soo Kim Seoul National University Children's Hospital

Responsible Party: Hee-Soo Kim, MD, PhD, Professor, Seoul National University Hospital
ClinicalTrials.gov Identifier: NCT03173014     History of Changes
Other Study ID Numbers: 1705-013-851
First Posted: June 1, 2017    Key Record Dates
Last Update Posted: July 21, 2017
Last Verified: July 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Cerebral Arterial Diseases
Moyamoya Disease
Carotid Artery Diseases
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Intracranial Arterial Diseases
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases